ArticleCancer medicine2021

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Stéphane de Botton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.